Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655486 | 0.91 | LMNA (0.38) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL16167268 | 0.83 | LMNA (0.41) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL12814052 | 0.81 | SMN1; SMN2 (0.41) | LMNAALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL110223 | 0.80 | ALDH1A1 (0.46) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL2409030 | 0.79 | LMNA (0.35) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL906682 | 0.78 | ALDH1A1 (0.41) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL8196222 | 0.78 | ALDH1A1 (0.37) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL2169206 | 0.77 | LMNA (0.35) | LMNAALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL5665047 | 0.77 | ALDH1A1 (0.58) | LMNAALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL8609493 | 0.76 | ALDH1A1 (0.49) | LMNAALDH1A1EHMT2EHMT1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388650-A1 | OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF | ENOSI THERAPEUTICS CORP (US) | 2025-12-25 | — | — | US | disclosed |
| US-20240197853-A1 | MULTIVALENT CHOLERA MULTIEPITOPE FUSION ANTIGEN (MEFA) AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240115686-A1 | SHIGELLA MULTI-EPITOPE FUSION ANTIGEN PROTEINS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2023168426-A1 | COMPOSITIONS AND CELLS CONTAINING MIXTURES OF OLIGO-TRAP FUSION PROTEINS (OFPS) AND USES THEREOF | ENOSI THERAPEUTICS CORPORATION (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11725041-B2 | Immune-modulating compounds | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2023-08-15 | — | — | US | disclosed |
| US-20230203470-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | DADA2 FOUNDATION | 2023-06-29 | — | — | US | disclosed |
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | HALOZYME, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11529389-B2 | Delivering biological drugs to tissues | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022216734-A1 | MULTIVALENT CHOLERA MULTIEPITOPE FUSION ANTIGEN (MEFA) AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2021076610-A1 | SHIGELLA MULTI-EPITOPE FUSION ANTIGEN PROTEINS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-1998026277-A2 | APPARATUS AND METHOD FOR DETECTING AND IDENTIFYING INFECTIOUS AGENTS | PROLUME, LTD. (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997049434-A9 | HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES | — | 1998-05-07 | — | — | WO | disclosed |
| EP-0833665-A1 | COMPOSITIONS CONTAINING NUCLEIC ACIDS AND LIGANDS FOR THERAPEUTIC TREATMENT | PRIZM PHARMACEUTICALS, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997049434-A2 | HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES | PRIZM PHARMACEUTICALS, INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0776218-A2 | HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS | PRIZM PHARMACEUTICALS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996036362-A1 | COMPOSITIONS CONTAINING NUCLEIC ACIDS AND LIGANDS FOR THERAPEUTIC TREATMENT | PRIZM PHARMACEUTICALS, INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| US-5536820-A | Avidin-binding azo reagents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1996008274-A2 | CONJUGATES OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR WITH TARGETED AGENTS | PRIZM PHARMACEUTICALS, INC. (US) | 1996-03-21 | — | — | WO | disclosed |
| WO-1996006641-A1 | CONJUGATES OF VASCULAR ENDOTHELIAL GROWTH FACTOR WITH TARGETED AGENTS | PRIZM PHARMACEUTICALS, INC. (US) | 1996-03-07 | — | — | WO | disclosed |
| WO-1995024928-A2 | HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS | PRIZM PHARMACEUTICALS, INC. (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | ADA, CDA, ADAR | LMNA 2327/4885ALDH1A1 339/4885EHMT2 976/4885 |
| US-20230203470-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | ADA, CDA, ADAR | LMNA 2327/4885ALDH1A1 339/4885EHMT2 976/4885 |
| US-20250388650-A1 | OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF | TNFSF11, TNFRSF9, FCER2 | LMNA 4558/4885ALDH1A1 4843/4885EHMT2 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.